2023
Liebert A, Shapiro M, Maradana MR, Li Y, Powell N, Zilbauer M, Stockinger B. Dysregulation of the Environmental Sensor Aryl Hydrocarbon Receptor Affects Differentiation of Human Colon Organoids. Cellular and Molecular Gastroenterology and Hepatology. 2023; doi: 10.1016/j.jcmgh.2023.11.002.
Liu Z, Alexander JL, Eng KY, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Seoane RC, Bewshea C, Nice R, D'Mello A, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Hart AL, Lees CW, Goodhand JR, Kennedy NA, Pollock KM, Ahmad T, Powell N; VIP study investigators. Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib. Journal of Crohn's and Colitis. 2023; doi: 10.1093/ecco-jcc/jjad182.
Lo JW, Cozzetto D, Alexander JL, Danckert NP, Madgwick M, Knox N, Sieh JYX, Olbei M, Liu Z, Ibraheim H, Blanco JM, Kudo H, Seoane RC, Possamai LA, Goldin R, Marchesi J, Korcsmaros T, Lord GM, Powell N. Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis. Nature Communications. 2023; Volume 14, Article number 6719.
Liu Z, Alexander JL, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin KW, McFarlane LR, Constable L, Seoane RC, Anand N, Bewshea C, Nice R, D'Mello A, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HR, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Hart AL, Lees CW, Goodhand JR, Kennedy NA, Pollock KM, Ahmad T, Powell N. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. EClinicalMedicine. 2023; Volume 64, 102249.
Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman ÅK, Kalnapenkis A, Enroth S, Cozzetto D, Digby-Bell J, Marten J, Folkersen L, Herder C, Jonsson L, Bergen SE, Gieger C, Needham EJ, Surendran P; Estonian Biobank Research Team; Paul DS, Polasek O, Thorand B, Grallert H, Roden M, Võsa U, Esko T, Hayward C, Johansson Å, Gyllensten U, Powell N, Hansson O, Mattsson-Carlgren N, Joshi PK, Danesh J, Padyukov L, Klareskog L, Landén M, Wilson JF, Siegbahn A, Wallentin L, Mälarstig A, Butterworth AS, Peters JE. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nature Immunology. 2023; Volume 24, Issue 9, Pages 1540-1551.
Shirwaikar Thomas A, Lee SE, Shatila M, De Toni EN, Török HP, Ben Khaled N, Powell N, Weight R, Faleck DM, Wang Y. IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience. American Journal of Gastroenterology. 2023; Volume 118; Issue 9; Pages 1679-1683.
Schroeder JH, Beattie G, Lo JW, Zabinski T, Powell N, Neves JF, Jenner RG, Lord GM. CD90 is not constitutively expressed in functional innate lymphoid cells. Frontiers in Immunology. 2023; Volume 14:1113735.
Steere B, Schmitz J, Powell N, Higgs R, Gottlieb K, Liu Y, Jia B, Tuttle JL, Sandborn WJ, Sands BE, D'Haens G, Reinisch W, Krishnan V. Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. Clinical and Translational Gastroenterology. 2023; Volume 14, Issue 7, Page e00578.
Alexander JL, Wyatt NJ, Camuzeaux S, Chekmeneva E, Jimenez B, Sands CJ, Fuller H, Takis P, Ahmad T, Doyle JA, Hart A, Irving PM, Kennedy NA, Lees CW, Lindsay JO, McIntyre RE, Parkes M, Prescott NJ, Raine T, Satsangi J, Speight RA, Jostins-Dean L, Powell N, Marchesi JR, Stewart CJ, Lamb CA. Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research. Gut 2023; doi: 10.1136/gutjnl-2022-329297.
Lees CW, Ahmad T, Lamb CA, Powell N, Din S, Cooney R, Kennedy NA, Ainley R, Wakeman R, Selinger CP. Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut 2023; Volume 72, Issue 2, Pages 410-412.
Liu Z, Alexander JL, Lin KW; VIP Study Investigators, Ahmad T, Pollock KM, Powell N. Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients Following 3 Doses of COVID-19 Vaccine. Gastroenterology 2023; Volume 164, Issue 2, Pages 300-303.
Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, Bewshea CM, Nice R, Lin S, Prabhudev H, Sands C, Horneffer-van der Sluis V, Lewis M, Sebastian S, Lees CW, Teare JP, Hart A, Goodhand JR, Kennedy NA, Korcsmaros T, Marchesi JR, Ahmad T, Powell N. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. EBioMedicine 2023; Volume 88:104430.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RC, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut 2023; Volume 72, Issue 2, Pages 295-305.
2022
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Lancet Gastroenterology & Hepatology 2022; Volume 8, Issue 2, Pages 145-156.
Akbar A, Orchard T, Powell N, Selinger C, Tibbatts C. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterology 2022; Volume 13, Issue 6, Pages 490-496.
Pavlidis P, Joshi D, El Sherif Y, Warner B, Gulati S, Alexander J, Cross G, Dew T, Arqoub HA, Devlin J, Heneghan M, Dubois P, Bjarnason I, Powell N, Hayee B. Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease. Frontline Gastroenterology 2022; Volume 13, Issue 6, Pages 497-502.
Pavlidis P, Tsakmaki A, Pantazi E, Li K, Cozzetto D, Digby-Bell J, Yang F, Lo JW, Alberts E, Sa ACC, Niazi U, Friedman J, Long AK, Ding Y, Carey CD, Lamb C, Saqi M, Madgwick M, Gul L, Treveil A, Korcsmaros T, Macdonald TT, Lord GM, Bewick G, Powell N. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nature Communications 2022; Volume 13, Article number 5820.
Pavlidis P, Tsakmaki A, Treveil A, Li K, Cozzetto D, Yang F, Niazi U, Hayee BH, Saqi M, Friedman J, Korcsmaros T, Bewick G, Powell N. Cytokine responsive networks in human colonic epithelial organoids unveil a molecular classification of inflammatory bowel disease. Cell Reports 2022; Volume 40, Issue 13, 111439.
Alexander JL, Ibraheim H, Richards C, Shum B, Pavlidis P, Hunter N, Teare JP, Wotherspoon A, Furness A, Turajlic S, Pickering L, Larkin J, Speight A, Papa S, Powell N. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. Journal for Immunotheraphy of Cancer 2022; Volume 10, Issue 9, e005490.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Goodhand JR, Hart AL, Lees CW, Boyton RJ, Kennedy NA, Ahmad T, Powell N; VIP study investigators. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterology & Hepatology 2022; S2468-1253(22)00274-6.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications 2022; Volume 13, Article number 1379.
Thomas JP, Modos D, Rushbrook SM, Powell N, Korcsmaros T. The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease. Frontiers in Immunology 2022; 13:829525.
Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Goodhand JR, Hart AL, Lees CW, Ahmad T, Powell N; VIP study investigators. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterology & Hepatology 2022; Volume 7, Issue 4, Pages 342-352.
Lo JW, de Mucha MV, Henderson S, Roberts LB, Constable LE, Garrido-Mesa N, Hertweck A, Stolarczyk E, Houlder EL, Jackson I, MacDonald AS, Powell N, Neves JF, Howard JK, Jenner RG, Lord GM. A population of naive-like CD4+ T cells stably polarized to the TH 1 lineage. European Journal of Immunology 2022; Volume 52, Issue 4, Pages 566-581.
Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022; Volume 162, Issue 5, Pages 1525-1542.
Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Alimentary Pharmacololy & Therapeutics 2022; Volume 55, Issue 1, Pages 26-48.
2021
Alexander JL, Selinger CP, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group. Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. Lancet Gastroenterology & Hepatology 2021; Volume 6, Issue 12, Pages 987-988.
Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, Greathead L, Griffiths RL, Ibraheim H, Kelleher P, Kok KB, Lees CW, MacDonald J, Sebastian S, Smith PJ, McDonald TJ, Irving PM, Powell N, Kennedy NA, Goodhand JR, Ahmad T. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn’s and Colitis 2022; Volume 16, Issue 3, Pages 389-397.
Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. Journal for Immunotherapy of Cancer 2021; Volume 9, Issue 7, e002742.
Hopkins CWP, Powell N, Norton C, Dumbrill JL, Hayee B, Moulton CD. Cognitive Impairment in Adult Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of the Academy of Consultation-Liaison Psychiatry 2021; Volume 6, Issue 4, Pages 387-403.
Alexander JL, Kennedy NA, Lees CW, Ahmad T, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply. Lancet Gastroenterology & Hepatology 2021; Volume 6, Issue 7, Pages :523-524.
Alexander JL, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group. SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change? Lancet Gastroenterology & Hepatology 2021; Volume 6, Issue 7, Pages 528-529.
Talley NJ, Powell N, Walker MM, Jones MP, Ronkainen J, Forsberg A, Kjellström L, Hellström PM, Aro P, Wallner B, Agréus L, Andreasson A. Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population-based studies. Alimentary Pharmacololy & Therapeutics 2021; Volume 54, Issue 1, Pages 32-42.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021; Volume 70, Issue 10, Pages 1884-1893.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 2021; Volume 70, Issue 5, Pages 865-875.
Schroeder JH, Meissl K, Hromadová D, Lo JW, Neves JF, Howard JK, Helmby H, Powell N, Strobl B, Lord GM. T-Bet Controls Cellularity of Intestinal Group 3 Innate Lymphoid Cells. Frontiers in Immunology 2021; 11:623324.
Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Selinger CP, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees CW, Dobson L, Wakeman R, Iqbal TH, Arnott I, Powell N; Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterology & Hepatology 2021; Volume 6, Issue 3, Pages 218-224.
2020
Talley NJ, Alexander JL, Walker MM, Jones MP, Hugerth LW, Engstrand L, Agréus L, Powell N, Andreasson A. Ileocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study. Clinical and Translational Gastroenterology 2020; Volume 12, Issue 1, :e00296.
Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Alimentary Pharmacololy & Therapeutics 2020; Volume 52, Issue 9, Pages 1432-1452.
Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, Chauhan D, Turajlic S, Powell N, Larkin JM, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open 2020; Volume 5, Issue 4, e000585.
Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The Lancet Gastroenterology & Hepatology 2020; Volume 5, Issue 7, Pages 679-697.
Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2020; Volume 69, Issue 10, Pages 1769-1777.
Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020; Volume 69, Issue 6, Pages 984-990.
Omer OS, Powell N, Lord GM. Characterizing Innate Lymphoid Cell Phenotype and Function in Human Inflammatory Bowel Disease. Methods in Molecular Biology 2020; Volume 2121, Pages 199-211.
Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Annals of gastroenterology 2020; Volume 33, Issue 2, Pages 170-177.
Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Mechanisms of checkpoint inhibition-induced adverse events. Clinical & Experimental Immunology 2020; Volume 200, Issue 2, Pages 141-154.
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology 2020; Volume 38, Issue 6, Pages 576-583.
Powell N, Pantazi E, Pavlidis P, Tsakmaki A, Li K, Yang F, Parker A, Pin C, Cozzetto D, Minns D, Stolarczyk E, Saveljeva S, Mohamed R, Lavender P, Afzali B, Digby-Bell J, Tjir-Li T, Kaser A, Friedman J, MacDonald TT, Bewick GA, Lord GM. Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. Gut. 2020; Volume 69, Issue 3, Pages 578-590.
Digby-Bell J.L., Atreya R., Monteleone G., Powell N. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 2020; Volume 17, Issue 1, Pages 9-20.
Taylor KM, Hanscombe KB, Prescott NJ, Iniesta R, Traylor M, Taylor NS, Fong S, Powell N, Irving PM, Anderson SH, Mathew CG, Lewis CM, Sanderson JD. Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology 2020; Volume 18, Issue 4, Pages 908-916.
Moulton CD, Norton C, Powell N, Mohamedali Z, Hopkins CWP. Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Gut 2020; Volume 69, Issue 3, Pages 609-610.
2019
Samaan MA, Powell N, Irving PM. Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often? Alimentary Pharmacololy & Therapeutics 2019; Volume 50, Issue 4, Pages 472-473.
Pantazi E, Powell N. Group 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?! Frontiers in Immunology 2019; 10:676.
Ibraheim H, Green M, Papa S, Powell N. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. BMJ Case Reports 2019; Volume 12, Issue 4, Page e226481.
Moulton CD, Hopkins CWP, Mohamedali Z, Powell N. Out of Sight, Out of Mind: The Limitations of the Hospital Anxiety and Depression Scale in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; Volume 25, Issue 8, :Page e100.
Moulton CD, Pavlidis P, Norton C, Norton S, Pariante C, Hayee B, Powell N. Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation? Clinical and Experimental Immunology 2019; Volume 197, Issue 3, Pages 308–318.
Garrido-Mesa N, Schroeder JH, Stolarczyk E, Gallagher AL, Lo JW, Bailey C, Campbell L, Sexl V, MacDonald TT, Howard JK, Grencis RK, Powell N, Lord GM. T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function. Mucosal Immunology 2019; Volume 12, Issue 1, Pages 51-63.
Ibraheim H., Perucha E., Powell N. Pathology of immune-mediated tissue
lesions following treatment with immune checkpoint inhibitors. Rheumatology 2019, Volume 58, Issue Supplement_7, Pages vii17–vii28.Alexander JL, Kohoutova D, Powell N. Science in Focus: The Microbiome and Cancer Therapy. Clinical Oncology 2019, Volume 31, Issue 1, Pages 1-4.
2018
Povoleri GAM, Nova-Lamperti E, Scottà C, Fanelli G, Chen YC, Becker PD, Boardman D, Costantini B, Romano M, Pavlidis P, McGregor R, Pantazi E, Chauss D, Sun HW, Shih HY, Cousins DJ, Cooper N, Powell N, Kemper C, Pirooznia M, Laurence A, Kordasti S, Kazemian M, Lombardi G, Afzali B. Human retinoic acid-regulated CD161+ regulatory T cells support wound repair in intestinal mucosa. Nature Immunology 2018; Volume 19, Issue 12, Pages 1403-1414.
Arbore G, West EE, Rahman J, Le Friec G, Niyonzima N, Pirooznia M, Tunc I, Pavlidis P, Powell N, Li Y, Liu P, Servais A, Couzi L, Fremeaux-Bacchi V, Placais L, Ferraro A, Walsh PR, Kavanagh D, Afzali B, Lavender P, Lachmann HJ, Kemper C. Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. Nature Communactions 2018; Volume 9, Issue 1, Article number 4186.
Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterology 2018; Volume 9, Issue 3, Pages 221-231.
Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nature Reviews Gastroenterology & Hepatology 2018; Volume 15, Issue 4, Pages 222-234.
Fricker M, Goggins BJ, Mateer S, Jones B, Kim RY, Gellatly SL, Jarnicki AG, Powell N, Oliver BG, Radford-Smith G, Talley NJ, Walker MM, Keely S, Hansbro PM. Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight 2018; Volume 3, Issue 3, Page e94040.
Ibraheim H, Giacomini C, Kassam Z, Dazzi F, Powell N. Advances in mesenchymal stromal cell therapy in the management of Crohn's disease. Expert Review of Gastroenterology & Hepatology 2018; Volume 12, Issue 2, Pages 141-153.
Previous years
Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I, Fong S, Goldberg R, Patel K, Gulati S, Medcalf L, Sastrillo M, Brown-Clarke C, Bidewell-Sullivan J, Forsyth K, Lee E, Stanton A, Duncan J, Chung-Faye G, Dubois P, Powell N, Anderson S, Sanderson J, Hayee B, Irving PM. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterology 2017; Volume 8, Issue 3, Pages 196-202.
Halim L, Romano M, McGregor R, Correa I, Pavlidis P, Grageda N, Hoong SJ, Yuksel M, Jassem W, Hannen RF, Ong M, Mckinney O, Hayee B, Karagiannis SN, Powell N, Lechler RI, Nova-Lamperti E, Lombardi G. An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. Cell Reports 2017; Volume 20, Issue 3, Pages 757-770.
Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clinical and Experimental Gastroenterology 2017; Volume 10, Pages 57-66.
Powell N., MacDonald T.T. Recent advances in gut immunology. Parasite immunology 2017; Volume 39, Issue 6, Page e12430.
Powell N., Walker M.M., Talley N.J. The mucosal immune system: master regulator of bidirectional gut-brain communications. Nature Reviews Gastroenterology & Hepatology 2017; Volume 14, Issue 3, Pages 143-59.
Lam EP, Kariyawasam HH, Rana BM, Durham SR, McKenzie AN, Powell N, Orban N, Lennartz-Walker M, Hopkins C, Ying S, Rimmer J, Lund VJ, Cousins DJ, Till SJ. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. Journal of Allergy and Clinical Immunology 2016; Volume 137, Issue 5, Pages 1514-24.
Canavan JB, Scottà C, Vossenkämper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, Fazekasova H, Irving PM, Sanderson JD, Howard JK, Yagel S, Afzali B, MacDonald TT, Hernandez-Fuentes MP, Shpigel NY, Lombardi G, Lord GM. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut 2016; Volume 65, Issue 4, Pages 584-94.
Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: bile acids and intestinal inflammation‐luminal aggressors or regulators of mucosal defence?. Alimentary pharmacology & therapeutics 2015; 42(7):802-17.
Powell N, Lo JW, Stolarczyk E., et al Interleukin 6 Increases Production of Cytokines by Innate Lymphoid Cells in Colon Tissues from Mice with Colitis and Patients with Inflammatory Bowel Disease. Gastroenterology 2015; 149:456-467.
Goldberg R, Prescott N, Lord GM, MacDonald TT, Powell N. The unusual suspects - innate lymphoid cells: novel therapeutic targets in IBD. Nature Reviews in Gastroenterology and Hepatology 2015; 12:271-283
Powell N, Lo JW, Kudo H, Stolarczyk E, Garrido-Mesa N, Hedley R, Jackson I, Goldin R, MacDonald TT, Lord GM. NKp46(+) innate lymphocytes mediate interferon-gamma -dependent acute hepatitis following activation of the CD40 pathway. Immunology 2014; 143:99
Powell N., Walker A.W., Stolarcyzk E., Canavan J.B., Gokmen R., Marks E., Jackson I., Hashim A., Curtis M., Howard J.K., Parkhill J., MacDonald T.T., Lord G.M. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity 2012; 37:674-84.
Powell N. The Use of Cecal and Terminal lleal Images for Verifying the Completion of Colonoscopy. Gastroenterol. Hepatol. 2011; 7(8):536-539
Powell N., Knight H., Dunn J., Saxena V., Mawdsley J., Murray C., Hoare J., Teare J., McNair A. Images of the terminal ileum are more convincing than cecal images for verifying the extent of colonoscopy. Endoscopy 2011; 43(3):196-201
Powell N., Canavan J.B., MacDonald T.T., Lord G.M. Transcriptional regulation of the mucosal immune system mediated by T-bet. Mucosal Immunology 2010; 3(6):567-577
Powell N, Walker MM, Talley NJ. Gastrointestinal eosinophils in health, disease and functional disorders. Nature Reviews Gastroenterology and Hepatology 2010; 7(3):146.